Combination antihypertensive therapy in patients with arterial hypertension and coronary heart disease

Abstract

The leading positions in the treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD) are held by angiotensin-converting enzyme (ACE) inhibitors and beta-adrenoblockers (BAB), which have demonstrated their effectiveness in terms of improved patients’ survival. In patients with AH and CHD, the rational, pathogenetic pharmacotherapy using a combination of an ACE inhibitor zofenopril and a highly cardio-selective and vasodilating BAB nebivolol demonstrates antihypertensive and antiischemic action, decreases the risk of potential adverse cardio-metabolic effects, reduces the severity of endothelial dysfunction, and, consequently, improves quality of life.

Keywords

• arterial hypertension
• coronary heart disease
• beta-adrenoblockers
• nebivolol
• ace inhibitors
• zofenopril